NEW YORK (GenomeWeb News) – GenMark Diagnostics and Advanced Liquid Logic today said they have executed definitive agreements to co-develop an all-digital, fully integrated in vitro diagnostic platform combining ALL's electrowetting technology and GenMark's electrochemical detection.
Today's agreement follows a preliminary deal announced by the firms earlier this year to develop the diagnostics platform. As part of the deal, Carlsbad, Calif.-based GenMark will pay ALL up to $3 million in license fees, contingent milestone payments, and an equity investment.
ALL, based in Durham, NC, develops microfluidics products for newborn screening and genomic sample preparation.